Heart Failure Clinical Trial
— MECHADOfficial title:
Metabolic Characterization of Patients With Dilated Cardiomyopathy a Prospective Case-control Study
NCT number | NCT05284682 |
Other study ID # | MECHAD |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 2022 |
Est. completion date | January 2026 |
The overall aim of the study is to explore the energy metabolism of the failing heart. Primary objective is to understand the differences in the energy metabolism in patients with DCM and heart failure compared to matched controls without heart failure. Secondary objectives, is to understand if optimal medical therapy, including sodium-gucose transporter 2 inhibitors (SGLT2i), alter the cardiac metabolism in DCM-patients. The investigators will also examine if changes in cardiac metabolism happens during exercise in patients with DCM. This will be done with invasive measurements of a range of energy substrate metabolites in the coronary sinus of the heart in patients with heart failure due to DCM and controls without heart failure respectively. A range of other clinical characteristics will also be examined to characterize patients and controls.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | January 2026 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | For cases (Heart Failure on the basis of DCM) Inclusion Criteria: - Signed and dated the Informed Consent Form - Male and female subjects =18 years of age - Chronic Heart failure (HF) with LVEF =40% - HF due to dilated cardiomyopathy (DCM) - New York Heart Association (NYHA) class =2 - Treatment with basic optimal medical therapy. - Clinical indication for invasive evaluation of heart failure Exclusion Criteria: - Life expectancy < 3 years due to other reasons than cardiovascular, cardiac transplantation or left ventricular assist device - Diabetes mellitus type 1 and 2 - Known hereditary hypercholesterolemia - Ongoing lipid lowering therapy - Patients on ketogenic diets - BMI>35 or <19 - Pregnancy - Any current life-threatening cardiac dysrhythmia, cardiac surgery, acute coronary syndrome, or non-elective percutaneous coronary intervention (PCI) <3 months - Current significant major or unstable respiratory disease - Considerable hematological disease, hepatic disease, renal disease and/or gastrointestinal disease - Stroke, transient ischemic attack, carotid surgery or angioplasty <3months - estimated glomerular filtration rate (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI formula) <30 mL/min/1.73m2 or patients on renal dialysis - Expected inability (by the investigator) to comply with the protocol - Subjects incapable to giving consent personally For control subjects (no heart failure) Inclusion criteria: - Signed and dated Informed Consent Form - Male and female subjects =18 years of age - Clinical indication for electrophysiology examination Exclusion criteria: - Heart Failure (HFpEF, heart failure with mid-range ejection fraction (HFmrEF) or HFrEF) - Life expectancy < 3 years due to other reasons than cardiovascular, cardiac transplantation or left ventricular assist device - Diabetes mellitus type 1 and 2 - Known hereditary hypercholesterolemia - Ongoing lipid lowering therapy - Patients on ketogenic diets - BMI>35 or <19 - Pregnancy - Any current life-threatening cardiac dysrhythmia, cardiac surgery, acute coronary syndrome, or non-elective PCI <3 months - Current significant major or unstable respiratory disease - Considerable hematological disease, hepatic disease, renal disease and/or gastrointestinal disease - Stroke, transient ischemic attack, carotid surgery or angioplasty <3months, - eGFR by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI formula) <30 mL/min/1.73m2 or patients on renal dialysis - Expected inability (by the investigator) to comply with the protocol - Subjects incapable to giving consent personally |
Country | Name | City | State |
---|---|---|---|
Sweden | Sahlgrenska University Hospital | Gothenburg | Western Sweden |
Lead Sponsor | Collaborator |
---|---|
Göteborg University | Sahlgrenska University Hospital, Sweden |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Metabolic markers | Energy substrate metabolic markers in arterial blood and coronary sinus for the calculation of energy metabolism in the myocardium. | through study completion, on average 2 years | |
Secondary | Metabolic markers after medical optimization | Energy substrate metabolic markers in arterial blood and coronary sinus for the calculation of energy metabolism in the myocardium. | through study completion, on average 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|